Abstract
The aim of this study was to evaluate the impact of inflammation on voriconazole (VRCZ) metabolism at three age groups in the allogeneic hematopoietic cell transplant recipients of the Chinese population. The study was performed with collecting more than one VRCZ trough concentration and C-reactive protein (CRP) levels. Longitudinal analysis, correlation and comparative analysis were conducted to evaluate. A total of 104 patients with 386 VRCZ trough concentration and CRP level measured on the same day were collected. For children, CRP levels significantly associated with VRCZ pharmacokinetics in age 11–18 years but not in age 2–10 years. For adults, VRCZ concentrations were increased slightly by 0.006 mg/L when every 1 mg/L increased in CRP levels. Additionally, meropenem and inflammation might work together to cause a higher VRCZ concentration. Therefore, therapeutic drug monitoring of VRCZ should be warranted at age >10 years in allogeneic hematopoietic cell transplant recipients with elevated CRP level.
Disclosure statement
The authors declare that they have no conflict of interest.
Additional information
Funding
Notes on contributors
Xingxian Luo
Xingxian Luo, Master, Department of Pharmacy, Peking University People's Hospital, Beijing, China (https://www.pkuph.cn/yjk_department.html). Therapeutic Drug Monitoring, Epigenetic regulation of cytochrome P450s, Pharmacogenetics, and Drug-drug interaction.
Taifeng Li
Taifeng Li, Master, Department of Pharmacy, Peking University People's Hospital, Beijing, China (https://www.pkuph.cn/yjk_department.html). Population pharmacokinetics, Biopharmaceutical analysis and Personalized medicine.
Lei Hu
Lei Hu, Doctor, Department of Pharmacy, Peking University People's Hospital, Beijing, China (https://www.pkuph.cn/yjk_department.html). Pharmacogenetics, Population pharmacokinetics, Biopharmaceutical analysis and personalized medicine.
Silu Liu
Silu Liu, Master, Department of Pharmacy, Peking University People's Hospital, Beijing, China (https://www.pkuph.cn/yjk_department.html). Pharmacogenetics, In vitro anti-infection study and Therapeutic Drug Monitoring.
Haiyan Zhao
Haiyan Zhao, Master, Department of Pharmacy, Peking University People's Hospital, Beijing, China (https://www.pkuph.cn/yjk_department.html). Therapeutic Drug Monitoring and Personalized medicine.
Jiaqi Zhang
Jiaqi Zhan, Bachelor, Department of Pharmacy, Peking University People's Hospital, Beijing, China (https://www.pkuph.cn/yjk_department.html). Therapeutic Drug Monitoring and Evidence-based medicine.
Yufei Feng
Yufei Feng, Master. Department of Pharmacy, Peking University People's Hospital, Beijing, China (https://www.pkuph.cn/yjk_department.html). Therapeutic Drug Monitoring, Pharmacoeconomics, and Evidence-based medicine.Lin Huang, Doctor, Department of Pharmacy, Peking University People's Hospital, Beijing, China (https://www.pkuph.cn/yjk_department.html). Therapeutic Drug Monitoring, Drug-drug interaction, Pharmacogenetics and Evidence-based medicine.